基于EVA模型的成长期医药企业价值评估研究--以白云山医药公司为例  

Value Evaluation of Growing Pharmaceutical Enterprises Based on the EVA Model:Taking Bai Yunshan Pharmaceutical Company as an Example

作　　者：江芸 JIANG Yun(School of Finance and Economics,Guangdong Agricultural,Industrial and BusinessPolytechnic,Guangzhou,Guangdong 510507,China)

机构地区：[1]广东农工商职业技术学院,广东广州510507

出　　处：《山东商业职业技术学院学报》2022年第5期9-16,共8页Journal of Shandong Institute of Commerce and Technology

基　　金：广东省教育科学“十三五”规划项目“粤港澳大湾区需求下‘1+X’证书制度与高职会计人才培养方案融合模型构建”(2020GXJK561)。

摘　　要：医改政策的不断推出,迫使我国医药企业向创新驱动发展转型及重组整合。有效评估医药企业的内在价值,有利于其实现企业价值最大化的目标,但目前针对医药企业特点的价值评估研究较少。根据成长期医药企业高投入、高风险的特点,以白云山为例,采用改进的沃尔评分法分析其财务状况,应用经济增加值(EVA)价值评估模型,计算白云山的股东全部权益价值,并对评估结果进行分析,验证其有效性,以期为我国医药企业进行价值管理提供参考。With the continuous introduction of medical reform policies,pharmaceutical enterprises are forced to innovate and reorganize.Effectively assessing the intrinsic value of pharmaceutical enterprises is conducive to their goal of maximizing corporate value,but there are few researches on value assessment based on the characteristics of pharmaceutical companies.Considering the high-investment and high-risk characteristics in growing pharmaceutical enterprises,taking Bai Yunshan as an example,this paper uses the improved Wole scoring method to analyze Bai Yunshan’s financial status,and then applies the EVA evaluation model to calculate total equity value.Finally,the validity of EVA evaluation model on pharmaceutical enterprises is evaluated,which can provide a reference for the value management of the pharmaceutical enterprises.

关 键 词：价值评估 经济增加值 沃尔评分法 成长期医药企业 

分 类 号：F275[经济管理—企业管理]